MGI Pharma To Buy Guilford - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

MGI Pharma To Buy Guilford

ePT--the Electronic Newsletter of Pharmaceutical Technology

MGI Pharma To Buy Guilford MGI Pharma To Buy Guilford

MGI Pharma (Minneapolis, MN) signed a merger agreement on July 20 to purchase Guilford Pharmaceuticals (Baltimore, MD) for approximately $177.5 million. MGI Pharma plans to advance creation of an acute care business and enhance their existing oncology franchise.

The merger also gives several important assets to MGI Pharma, including Aquavan, a late-stage, acute care product candidate for procedural sedation; Gliadel, a marketed product for high-grade malignant gliomas that complements MGI Pharma’s current oncology franchise; and the Guilford field organization.

“Moreover, the addition of two early stage programs, NAALADase inhibitors for chemotherapy-induced neuropathy, and PARP inhibitors, as chemotherapy or radiation therapy sensitizers, fit strategically into our oncology development pipeline,” said Lonnie Moulder, president and CEO of MGI Pharma, in a prepared statement.

Upon closing of this agreement, a director of Guilford Pharmaceuticals will be nominated to join the MGI Pharma board of directors. The acquisition, which has been approved by the boards of directors of both companies, is subject to Guilford stockholder approval and other customary closing conditions, and is expected to close during the fourth quarter of 2005.

–George Koroneos

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
30%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
30%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here